dc.contributor | Saavedra Trujillo, Carlos Humberto | |
dc.contributor | Echeverry Gaitán, María Clara | |
dc.contributor | Pérez Cely, Jairo Antonio | |
dc.contributor | Murcia Aranguren, Martha Isabel | |
dc.contributor | Eslava Schmalbach, Javier Hernando | |
dc.contributor | Montañez Ayala, Anita Maria | |
dc.contributor | Rodríguez Castillos, Juan German | |
dc.contributor | Grupo de Investigación: Grupo de infecciones y salud en el trópico | |
dc.creator | Salcedo Torres, David Ernesto | |
dc.date.accessioned | 2023-02-08T16:24:31Z | |
dc.date.accessioned | 2023-06-07T00:09:55Z | |
dc.date.available | 2023-02-08T16:24:31Z | |
dc.date.available | 2023-06-07T00:09:55Z | |
dc.date.created | 2023-02-08T16:24:31Z | |
dc.date.issued | 2023-01-25 | |
dc.identifier | https://repositorio.unal.edu.co/handle/unal/83382 | |
dc.identifier | Universidad Nacional de Colombia | |
dc.identifier | Repositorio Institucional Universidad Nacional de Colombia | |
dc.identifier | https://repositorio.unal.edu.co/ | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/6651779 | |
dc.description.abstract | Introducción: La mortalidad asociada a la infección por SARS CoV-2 varia en diferentes localizaciones geográficas, hallazgo en relación con la variabilidad en la población respecto a la prevalencia de comorbilidades, edad, la respuesta inmune del hospedador, entre otros. Se han descrito variantes genéticas del virus con fenotipos distintos, ya sea por cambios antigénicos, de la transmisibilidad o virulencia, y por tanto tener un impacto en la morbimortalidad
Objetivos: Determinar qué factores se asocian a muerte en los pacientes con COVID 19 que ingresan a la unidad de cuidado crítico y describir la frecuencia de las variantes de SARS CoV-2 en estos pacientes.
Materiales y métodos: Se realizó un estudio observacional analítico, retrospectivo tipo casos y controles para evaluar la asociación entre las variables clínicas, paraclínicas y sociodemográficas y el desenlace muerte, en los pacientes que ingresan a la unidad de cuidado crítico con diagnóstico de COVID 19, atendidos entre junio de 2020 y agosto de 2021.
Resultados: Un total de 88 pacientes fueron incluidos, 44 casos (desenlace muerte presente), en el análisis univariado se identificaron como factores de riesgo de muerte las variables edad mayor de 65 años OR 7.15 (2.79-18.32), neutrófilos mayores de 12 x 10*3/uL, 3.40 (1.35-8.53), creatinina sérica mayor de 1.3 OR 3.11 (1.17-8.24), Ingreso directo a UCI OR 5.40 (1.78-16.35), y requerimiento de soporte vasoactivo, ventilatorio y de terapia de reemplazo renal con ORs de 12.00 (2.55-56.30), 14.33 (1.76-116.67) y 14.53 (3.11-67.85) respectivamente.
Conclusiones: Los factores de riesgo identificados pueden ayudar a una estratificación acertada del riesgo de muerte y así mismo ayudar a determinar conductas tempranas de tratamiento y monitorización en la atención a pacientes con COVID 19 atendidos en la Unidad de Cuidado Critico.
Palabras clave: SARS CoV2, Variantes genéticas, Unidad de cuidado crítico, mortalidad (Texto tomado de la fuente) | |
dc.description.abstract | Introduction: The mortality associated with SARS CoV-2 infection varies in different
geographical locations, a finding related to the variability in the population regarding the
prevalence of comorbidities, age, the host's immune response, among others. Genetic
variants of the virus with different phenotypes have been described, either due to antigenic
changes, transmissibility or virulence, and therefore having an impact on morbimortality.
Objectives: To determine which factors are associated with death in patients with COVID
19 admitted to the critical care unit and to describe the frequency of SARS CoV-2 variants
in these patients.
Materials and methods: An analytical, retrospective observational case-control study will
be carried out to evaluate the association between clinical, paraclinical and
sociodemographic variables and the outcome of death, in patients admitted to the critical
care unit with a diagnosis of COVID 19, served between June 2020 and August 2021
Results: A total of 88 patients were included, 44 cases (death outcome present), were
identified as a risk factor for death the variables age over 65 years OR 7.15 (2.79-18.32),
neutrophils over 12 x 10*3/uL, 3.40 (1.35-8.53),serum creatinine greater than 1.3 OR 3.11
(1.17-8.24), direct admission to the ICU OR 5.40 (1.78-16.35) and requirement of
vasoactive, ventilatory support and renal replacement therapy with ORs of 12.00 (2.55-
56.30), 14.33 (1.76-116.67) y 14.53 (3.11-67.85) respectively.
Conclusions: The identified risk factors can help to accurately stratify the risk of death and
also help determine early treatment and monitoring behaviors in the care of patients with
COVID 19 treated in the Critical Care Unit . | |
dc.language | spa | |
dc.publisher | Universidad Nacional de Colombia | |
dc.publisher | Bogotá - Medicina - Especialidad en Infectología | |
dc.publisher | Facultad de Medicina | |
dc.publisher | Bogotá, Colombia | |
dc.publisher | Universidad Nacional de Colombia - Sede Bogotá | |
dc.relation | Cutler DM, Summers LH. The COVID-19 Pandemic and the $16 Trillion Virus. JAMA. 20 de octubre de 2020;324(15):1495. | |
dc.relation | Pak A, Adegboye OA, Adekunle AI, Rahman KM, McBryde ES, Eisen DP. Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness. Front Public Health. 29 de mayo de 2020;8:241. | |
dc.relation | Ortiz-Prado E, Simbaña-Rivera K, Gómez- Barreno L, Rubio-Neira M, Guaman LP, Kyriakidis NC, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. Diagnostic Microbiology and Infectious Disease. septiembre de 2020;98(1):115094. | |
dc.relation | Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. The Lancet Respiratory Medicine. mayo de 2020;8(5):506-17. | |
dc.relation | Cheng S, Wu D, Li J, Zou Y, Wan Y, Shen L, et al. Risk factors for the critical illness in SARS-CoV-2 infection: a multicenter retrospective cohort study. Respir Res. diciembre de 2020;21(1):277. | |
dc.relation | Zhang XB, Hu L, Ming Q, Wei XJ, Zhang ZY, Chen LD, et al. Risk factors for mortality of coronavirus disease-2019 (COVID-19) patients in two centers of Hubei province, China: A retrospective analysis. Lucas A, editor. PLoS ONE. 28 de enero de 2021;16(1):e0246030. | |
dc.relation | Chen Y, Linli Z, Lei Y, Yang Y, Liu Z, Xia Y, et al. Risk factors for mortality in critically ill patients with COVID‐19 in Huanggang, China: A single‐center multivariate pattern analysis. J Med Virol. abril de 2021;93(4):2046-55. | |
dc.relation | Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 26 de marzo de 2020;m1198. | |
dc.relation | Motta JC, Novoa DJ, Gómez CC, Moreno JM, Vargas L, Pérez J, et al. Factores pronósticos en pacientes hospitalizados con diagnóstico de infección por SARS-CoV-2 en Bogotá, Colombia. biomedica. 30 de octubre de 2020;40(Supl. 2):116-30. | |
dc.relation | Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. j intensive care. diciembre de 2020;8(1):36. | |
dc.relation | Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 1 de abril de 2021;592(7852):116-21. | |
dc.relation | Pucci F, Rooman M. Prediction and evolution of the molecular fitness of SARS-CoV-2 variants: Introducing SpikePro [Internet]. Bioinformatics; 2021 abr [citado 2 de mayo de 2021]. Disponible en: http://biorxiv.org/lookup/doi/10.1101/2021.04.11.439322 | |
dc.relation | Toyoshima Y, Nemoto K, Matsumoto S, Nakamura Y, Kiyotani K. SARS-CoV-2 genomic variations associated with mortality rate of COVID-19. J Hum Genet. diciembre de 2020;65(12):1075-82. | |
dc.relation | Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2—What Do They Mean? JAMA. 9 de febrero de 2021;325(6):529. | |
dc.relation | Amit S, Regev-Yochay G, Afek A, Kreiss Y, Leshem E. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients. The Lancet. febrero de 2021;S0140673621004487. | |
dc.relation | Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities. JAMA [Internet]. 17 de febrero de 2021 [citado 24 de febrero de 2021]; Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2776739 | |
dc.relation | Lineage P.1 [Internet]. [citado 1 de marzo de 2021]. Disponible en: https://cov-lineages.org/global_report_P.1.html | |
dc.relation | Noticias coronavirus-genoma [Internet]. [citado 14 de enero de 2023]. Disponible en: https://www.ins.gov.co/Noticias/Paginas/coronavirus-genoma.aspx | |
dc.relation | Pan F, Yang L, Li Y, Liang B, Li L, Ye T, et al. Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study. Int J Med Sci. 2020;17(9):1281-92. | |
dc.relation | The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 25 de febrero de 2021;384(8):693-704. | |
dc.relation | Kang SJ, Jung SI. Age-Related Morbidity and Mortality among Patients with COVID-19. Infect Chemother. 2020;52(2):154. | |
dc.relation | Hashim MJ, Alsuwaidi AR, Khan G. Population Risk Factors for COVID-19 Mortality in 93 Countries: JEGH. 2020;10(3):204. | |
dc.relation | Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. abril de 2020;87(4):281-6. | |
dc.relation | Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and SARS-COV-2. Turk J Med Sci. 21 de abril de 2020;50(SI-1):549-56. | |
dc.relation | Henry R. Etymologia: Coronavirus. Emerg Infect Dis. mayo de 2020;26(5):1027-1027. | |
dc.relation | Geller C, Varbanov M, Duval R. Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies. Viruses. 12 de noviembre de 2012;4(11):3044-68. | |
dc.relation | Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 8 de noviembre de 2012;367(19):1814-20. | |
dc.relation | Wu YC, Chen CS, Chan YJ. The outbreak of COVID-19: An overview. Journal of the Chinese Medical Association. marzo de 2020;83(3):217-20. | |
dc.relation | Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, et al. Coronavirus Disease 2019–COVID-19. Clin Microbiol Reviews. 24 de junio de 2020;33(4):e00028-20, /cmr/33/4/CMR.00028-20.atom. | |
dc.relation | Colombia confirma su primer caso de COVID-19 [Internet]. [citado 8 de mayo de 2021]. Disponible en: https://www.minsalud.gov.co/Paginas/Colombia-confirma-su-primer-caso-de-COVID-19.aspx | |
dc.relation | Weekly epidemiological update on COVID-19 - 4 May 2021 [Internet]. [citado 6 de mayo de 2021]. Disponible en: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---4-may-2021 | |
dc.relation | Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. Biochemical and Biophysical Research Communications. enero de 2021;538:88-91. | |
dc.relation | Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh IK, Singh A, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. octubre de 2020;1866(10):165878. | |
dc.relation | Rahimi A, Mirzazadeh A, Tavakolpour S. Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection. Genomics. enero de 2021;113(1):1221-32. | |
dc.relation | Khan MI, Khan ZA, Baig MH, Ahmad I, Farouk AE, Song YG, et al. Comparative genome analysis of novel coronavirus (SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight. Ashraf GM, editor. PLoS ONE. 3 de septiembre de 2020;15(9):e0238344. | |
dc.relation | Yoshimoto FK. A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2. Protein J [Internet]. 24 de febrero de 2021 [citado 25 de mayo de 2021]; Disponible en: http://link.springer.com/10.1007/s10930-021-09967-8 | |
dc.relation | Satarker S, Nampoothiri M. Structural Proteins in Severe Acute Respiratory Syndrome Coronavirus-2. Archives of Medical Research. agosto de 2020;51(6):482-91. | |
dc.relation | Wang MY, Zhao R, Gao LJ, Gao XF, Wang DP, Cao JM. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front Cell Infect Microbiol. 25 de noviembre de 2020;10:587269. | |
dc.relation | Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 29 de septiembre de 2016;3(1):237-61. | |
dc.relation | Bianchi M, Benvenuto D, Giovanetti M, Angeletti S, Ciccozzi M, Pascarella S. Sars-CoV-2 Envelope and Membrane Proteins: Structural Differences Linked to Virus Characteristics? BioMed Research International. 30 de mayo de 2020;2020:1-6. | |
dc.relation | Alharbi SN, Alrefaei AF. Comparison of the SARS-CoV-2 (2019-nCoV) M protein with its counterparts of SARS-CoV and MERS-CoV species. Journal of King Saud University - Science. marzo de 2021;33(2):101335. | |
dc.relation | Singh Tomar PP, Arkin IT. SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine. Biochemical and Biophysical Research Communications. septiembre de 2020;530(1):10-4. | |
dc.relation | Schoeman D, Fielding BC. Coronavirus envelope protein: current knowledge. Virol J. diciembre de 2019;16(1):69. | |
dc.relation | Cubuk J, Alston JJ, Incicco JJ, Singh S, Stuchell-Brereton MD, Ward MD, et al. The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nat Commun. diciembre de 2021;12(1):1936. | |
dc.relation | Wu C, Qavi AJ, Hachim A, Kavian N, Cole AR, Moyle AB, et al. Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain [Internet]. Biochemistry; 2020 nov [citado 25 de mayo de 2021]. Disponible en: http://biorxiv.org/lookup/doi/10.1101/2020.11.30.404905 | |
dc.relation | Liu DX, Fung TS, Chong KKL, Shukla A, Hilgenfeld R. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Research. septiembre de 2014;109:97-109. | |
dc.relation | Rehman S ur, Shafique L, Ihsan A, Liu Q. Evolutionary Trajectory for the Emergence of Novel Coronavirus SARS-CoV-2. Pathogens. 23 de marzo de 2020;9(3):240. | |
dc.relation | Koyama T, Platt D, Parida L. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ. 1 de julio de 2020;98(7):495-504. | |
dc.relation | Laamarti M, Alouane T, Kartti S, Chemao-Elfihri MW, Hakmi M, Essabbar A, et al. Large scale genomic analysis of 3067 SARS-CoV-2 genomes reveals a clonal geo-distribution and a rich genetic variations of hotspots mutations [Internet]. Genomics; 2020 may [citado 26 de mayo de 2021]. Disponible en: http://biorxiv.org/lookup/doi/10.1101/2020.05.03.074567 | |
dc.relation | Laha S, Chakraborty J, Das S, Manna SK, Biswas S, Chatterjee R. Characterizations of SARS-CoV-2 mutational profile, spike protein stability and viral transmission. Infection, Genetics and Evolution. noviembre de 2020;85:104445. | |
dc.relation | Shahhosseini N, Babuadze G (Giorgi), Wong G, Kobinger GP. Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern. Microorganisms. 26 de abril de 2021;9(5):926. | |
dc.relation | Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. noviembre de 2020;5(11):1403-7. | |
dc.relation | Tegally H, Wilkinson E, Lessells RR, Giandhari J, Pillay S, Msomi N, et al. Major new lineages of SARS-CoV-2 emerge and spread in South Africa during lockdown [Internet]. Infectious Diseases (except HIV/AIDS); 2020 oct [citado 27 de mayo de 2021]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2020.10.28.20221143 | |
dc.relation | Cella E, Benedetti F, Fabris S, Borsetti A, Pezzuto A, Ciotti M, et al. SARS-CoV-2 Lineages and Sub-Lineages Circulating Worldwide: A Dynamic Overview. Chemotherapy. 18 de marzo de 2021;1-5. | |
dc.relation | SARS-CoV-2 variants of concern as of 24 May 2021 [Internet]. European Centre for Disease Prevention and Control. [citado 26 de mayo de 2021]. Disponible en: https://www.ecdc.europa.eu/en/covid-19/variants-concern | |
dc.relation | CDC. Coronavirus Disease 2019 (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [citado 26 de mayo de 2021]. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html | |
dc.relation | Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. marzo de 2020;395(10229):1054-62. | |
dc.relation | Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Annals of Epidemiology. mayo de 2021;57:14-21. | |
dc.relation | Armstrong RA, Kane AD, Kursumovic E, Oglesby FC, Cook TM. Mortality in patients admitted to intensive care with COVID‐19: an updated systematic review and meta‐analysis of observational studies. Anaesthesia. abril de 2021;76(4):537-48. | |
dc.relation | Bravo LE, Grillo-Ardila EK, Bravo LE, Grillo-Ardila EK. Análisis de mortalidad por COVID-19 en Colombia: Medidas de ocurrencia. Universidad y Salud. diciembre de 2020;22(3):292-8. | |
dc.relation | Parohan M, Yaghoubi S, Seraji A, Javanbakht MH, Sarraf P, Djalali M. Risk factors for mortality in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies. The Aging Male. 4 de diciembre de 2020;23(5):1416-24. | |
dc.relation | Martins-Filho PR, Tavares CSS, Santos VS. Factors associated with mortality in patients with COVID-19. A quantitative evidence synthesis of clinical and laboratory data. European Journal of Internal Medicine. junio de 2020;76:97-9. | |
dc.relation | Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 9 de marzo de 2021;n579. | |
dc.relation | Zali A, Khodadoost M, Gholamzadeh S, Janbazi S, Piri H, Taraghikhah N, et al. Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Sci Rep. 7 de noviembre de 2022;12(1):18918. | |
dc.relation | E E, F M, A H, L M, C E. Impact of Lymphopenia on COVID-19 infection Severity Single-center experience. Hematol Med Oncol [Internet]. 2020 [citado 29 de mayo de 2021];5(4). Disponible en: https://www.oatext.com/impact-of-lymphopenia-on-covid-19-infection-severity-single-center-experience.php | |
dc.relation | Fathi N, Rezaei N. Lymphopenia in COVID‐19: Therapeutic opportunities. Cell Biol Int. septiembre de 2020;44(9):1792-7. | |
dc.relation | Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID‐19: Possible mechanisms. Scand J Immunol [Internet]. febrero de 2021 [citado 29 de mayo de 2021];93(2). Disponible en: https://onlinelibrary.wiley.com/doi/10.1111/sji.12967 | |
dc.relation | Lee J, Park SS, Kim TY, Lee DG, Kim DW. Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study. Cancers. 26 de enero de 2021;13(3):471. | |
dc.relation | Freed NE, Vlková M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biology Methods and Protocols. 1 de enero de 2020;5(1):bpaa014. | |
dc.relation | Sezen ysegul I, Senoglu S, Karabela SN, Yesilbag Z, Borcak D, Canbolat Unlu E, et al. Risk factors and the impact of vaccination on mortality in COVID-19 patients. BLL. 2022;123(06):440-3. | |
dc.relation | Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. diciembre de 2021;21(1):855. | |
dc.relation | Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection. julio de 2020;81(1):e6-12. | |
dc.relation | Arregocés-Castillo L, Fernández-Niño J, Rojas-Botero M, Palacios-Clavijo A, Galvis-Pedraza M, Rincón-Medrano L, et al. Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. The Lancet Healthy Longevity. abril de 2022;3(4):e242-52. | |
dc.relation | Andrade JA, Muzykovsky K, Truong J. Risk factors for mortality in COVID‐19 patients in a community teaching hospital. J Med Virol. mayo de 2021;93(5):3184-93. | |
dc.relation | Vo GV, Bagyinszky E, An SSA. COVID-19 Genetic Variants and Their Potential Impact in Vaccine Development. Microorganisms. 10 de marzo de 2022;10(3):598. | |
dc.relation | CMMID COVID-19 Working Group, Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 13 de mayo de 2021;593(7858):270-4. | |
dc.relation | Patone M, Thomas K, Hatch R, Tan PS, Coupland C, Liao W, et al. Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study. The Lancet Infectious Diseases. noviembre de 2021;21(11):1518-28. | |
dc.relation | Bonacorsi S, Visseaux B, Bouzid D, Pareja J, Rao SN, Manissero D, et al. Systematic Review on the Correlation of Quantitative PCR Cycle Threshold Values of Gastrointestinal Pathogens With Patient Clinical Presentation and Outcomes. Front Med. 23 de septiembre de 2021;8:711809. | |
dc.relation | Rico-Caballero V, Fernández M, Hurtado JC, Marcos MA, Cardozo C, Albiach L, et al. Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. Infection. octubre de 2022;50(5):1321-8. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | |
dc.rights | http://creativecommons.org/licenses/by-nc/4.0/ | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.title | Factores asociados a muerte y evaluación de variantes genéticas en pacientes adultos con covid 19 que ingresan a la unidad de cuidado crítico en el hospital universitario nacional de Colombia | |
dc.type | Trabajo de grado - Especialidad Médica | |